UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/117,838	08/12/1998	OLEG LLIICH EPHSTEIN	841/3	4128	
	7590 10/08/200 MAN GIBSON & DER	EXAMINER			
900 ROUTE 9 I WOODBRIDG		PESELEV, ELLI			
W OODBRIDG	E, 1NJ 07095		ART UNIT	PAPER NUMBER	
			1623		
		MAIL DATE	DELIVERY MODE		
			10/08/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary		Applica	tion No.	Applicant(s)	Applicant(s)	
		09/117	838	EPHSTEIN, OLEG LLIICH		
		Examin	er	Art Unit		
		Elli Pes	elev	1623		
The MAIL Period for Reply	ING DATE of this commur	nication appears on t	he cover sheet with th	ne correspondence ac	ddress	
A SHORTENED WHICHEVER IS - Extensions of time m after SIX (6) MONTH - If NO period for reply - Failure to reply within Any reply received by	STATUTORY PERIOD F LONGER, FROM THE May be available under the provisions S from the mailing date of this comin is specified above, the maximum single the set or extended period for reply to the Office later than three months djustment. See 37 CFR 1.704(b).	MAILING DATE OF sof 37 CFR 1.136(a). In no munication. tatutory period will apply and will, by statute, cause the a	THIS COMMUNICAT event, however, may a reply b will expire SIX (6) MONTHS to pplication to become ABANDO	ION. e timely filed from the mailing date of this of DNED (35 U.S.C. § 133).		
Status						
2a)⊠ This action 3)□ Since this	e to communication(s) file is FINAL. application is in condition ccordance with the pract	2b)☐ This action is for allowance exce	non-final. ot for formal matters,	prosecution as to the	e merits is	
Disposition of Clair	ns					
4a) Of the a 5) ☐ Claim(s) _ 6) ☑ Claim(s) <u>1</u> 7) ☐ Claim(s) _	7,19-21,23,25-27,29-34 above claim(s) is/a is/are allowed. 7, 19-21, 23, 25-27, 29-3- is/are objected to. are subject to restrice	are withdrawn from o	consideration.	n.		
Application Papers						
10) The drawing Applicant m	cation is objected to by the g(s) filed on is/are ay not request that any object drawing sheet(s) including declaration is objected to	: a) ☐ accepted or ection to the drawing(sg the correction is requ) be held in abeyance. uired if the drawing(s) is	See 37 CFR 1.85(a). objected to. See 37 C		
Priority under 35 U.	S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
	son's Patent Drawing Review (I ure Statement(s) (PTO/SB/08)	PTO-948)	4) Interview Summ Paper No(s)/Ma 5) Notice of Inform 6) Other:			

Application/Control Number: 09/117,838

Art Unit: 1623

Claims 45-48 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 45 is indefinite in that it depends from the cancelled claim 35.

Method claims 46-48 are indefinite in that the decease or condition being treated has not been set forth.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set f98orth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The following is a quotation of the appropriate paragraphs of 35

U.S.C. 102 that form the basis for the rejections under this section made in this

Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 17, 19-21, 23, 25-27 and 45-48 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Jonsson et al (U.S. Patent No. 4,292,324).

Jonsson et al disclose a method of making a pharmaceutical composition by combining one or more active substances and a method of treatment with said composition. Since the active substance and a homeopathic substance are chemically homogeneous, said substances encompass a compound having the

Application/Control Number: 09/117,838

Art Unit: 1623

same chemical structure and combining said substances into a single composition would inherently result in the prior art's composition

Claims 29 and 38 are rejected under 35 U.S.C. 102((b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Cohen et al (U.S. Patent No. 3,901,967).

Cohen et al disclose a pharmaceutical comprising atropine sulfate. The claimed composition comprising atropine sulfate and a homeophatic dilution of atropine sulfate is inherent in the prior art's composition.

Claims 30 and 39 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Sirany (U.S. Patent No. 4,987,127).

Sirany discloses a pharmaceutically composition comprising acetylsalicylic acid. The claimed composition comprising acetylsalicylic acid and a homeophatic dilution of acetylsalicylic acid is inherent in the prior art' composition.

Claims 31, 40 and 41 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Nobile (U.S. Patent No. 3,134,718).

Nobile discloses a pharmaceutical composition comprising Prednizolon.

The claimed medication comprising prednizolone and a homeophatic dilution of Prenizolone is inherent in the prior art's composition.

Application/Control Number: 09/117,838

Art Unit: 1623

Claims 32 and 42 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Massey (U.S. Patent No. 4,839,341).

Massey disclose a pharmaceutical composition of insulin. The claimed composition comprising insulin and a homeophatic dilution of insulin is inherent in the prior art's composition.

Claims 33 and 43 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Jonsson et al (U.S. Patent No. 4,292,342).

Jonsson et al disclose a pharmaceutical composition comprising zinc.

The claimed composition comprising zinc and a homeophatic dilution of zinc in inherent in the prior art's composition.

Claims 43 and 44 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Albert Stock John et al (U.S. Patent No. 3,032,584).

Albert Stock John et al disclose a pharmaceutical composition comprising Sarcolysin. The claimed composition comprising Sarcolysin and a homeophatic dilition of Sarcolysin, is inherent in the prior art's composition.

Applicant's arguments filed August 1, 2008 and September 10, 2008 have been fully considered but they are not persuasive.

Applicant contends that a therapeutic medicine and a homeophatic dilution of said medicine are not the same. This argument gas not been found persuasive since applicant has not pointed out how the structural formula of a

Art Unit: 1623

therapeutic medicine differs from the structural formula of a homeophatic dilution of said medicine. The claimed composition encompass nothing more than combining the same medicine in different concentration resulting in medicine which is patentably indistinguishable from the conventional medicine disclosed in the prior art of record.

Applicant further contends that the prior art of record does not disclose a therapeutically active compound that "possess enhanced therapeutic properties in comparison with said active medicine alone". This argument has not been found persuasive since applicant has not presented data comparing the claimed composition with the prior art's composition which is commensurate in scope with the claimed invention.

The declaration of Dr. Epstein filed 2/8/2008 has been considered.

The declaration does not present data relating to atropine sulfate, acetylsalicylic acid, insulin, zinc and sarcolysin encompassed by the present claims.

With respect to prednisolone, the declaration states that the combined administration of ultra low dose of prednisolone and prednisolone resulted in reduction of side effects. However, it is not clear from said statement the number of subjects treated and it is not clear from said statement the dosage of prednisolone itself administered. Therefore, the significance f the results presented cannot be ascertained.

It is still unclear how a ultra low dose of a medicine combined with the prior's medicine results in a different medicine being produced.

Art Unit: 1623

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elli Peselev whose telephone number is (571) 272-0659. The examiner can normally be reached on 8.00-4.30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shaojia Jiang can be reached on (571) 272-0627. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 09/117,838 Page 7

Art Unit: 1623

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Elli Peselev /Elli Peselev/ Primary Examiner, Art Unit 1623